Search research articles
Contact Us
Filters
Showing results (71-80 of 85) with videos related to
Page
of 9
Sort By:
Cancer Chemotherapy and Pharmacology
|
June 9, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, et al.
Breast Cancer Research and Treatment
|
June 2, 2019
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study
Manuel Ruíz-Borrego, Angel Guerrero-Zotano, Begoña Bermejo, et al.
Scientific Reports
|
December 29, 2019
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
Sara Lopez-Tarruella, M J Escudero, Marina Pollan, et al.
The Oncologist
|
July 14, 2017
Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis
Miguel Martín, José I Chacón, Antonio Antón, et al.
Cancer Cell
|
February 13, 2020
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers
Dhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2025
Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01)
Chiara Biagioni, Danai Fimereli, Alexandre Irrthum, et al.
Cancer Cell
|
January 25, 2020
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers
Dhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
Frankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Federico Rojo, Clive R Taylor, Carlos Barrios, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2026
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial
Miguel Martín, Alvaro Rodriguez-Lescure, Cristina Reboredo, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 85) with videos related to
Sort By:
Page
of 9
Cancer Chemotherapy and Pharmacology
|
June 9, 2018
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
Jordi Rodon, Alejandro Pérez-Fidalgo, Ian E Krop, et al.
Breast Cancer Research and Treatment
|
June 2, 2019
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study
Manuel Ruíz-Borrego, Angel Guerrero-Zotano, Begoña Bermejo, et al.
Scientific Reports
|
December 29, 2019
Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)
Sara Lopez-Tarruella, M J Escudero, Marina Pollan, et al.
The Oncologist
|
July 14, 2017
Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis
Miguel Martín, José I Chacón, Antonio Antón, et al.
Cancer Cell
|
February 13, 2020
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers
Dhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 22, 2025
Molecular and clinical analyses of gene fusions identify therapeutic targets in paired primary and metastatic breast cancer from the AURORA program (BIG 14-01)
Chiara Biagioni, Danai Fimereli, Alexandre Irrthum, et al.
Cancer Cell
|
January 25, 2020
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers
Dhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 10, 2023
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
Frankie A Holmes, Beverly Moy, Suzette Delaloge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Federico Rojo, Clive R Taylor, Carlos Barrios, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2026
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial
Miguel Martín, Alvaro Rodriguez-Lescure, Cristina Reboredo, et al.
Page
of 9